Collagen and heparin matrices for growth factor delivery

Schroeder-Tefft, J.A; Bentz, Hanne; Estridge, Trudy D.

doi:10.1016/s0168-3659(97)10055-4

Cited by 36 publications

(12 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, the actual amounts of Tgf-␤3 released from the collagen gel were not quantified in the perisutural tissues, and the sutures in the Tgf-␤3 groups may have received smaller amounts than anticipated. However, studies using this collagen gel vehicle have shown that Tgf-␤2 mixed with the collagen gel in culture retained a level of activity similar to that of Tgf-␤2 alone (Schroeder-Tefft et al, 1997;Bentz et al, 1998). The collagen lasted for at least 63 days in rabbit perisutural tissue, as observed by the use of biotinylated collagen gel (Moursi et al, unpublished data), and it showed no evidence of a localized inflammatory or generalized immune response following gel implantation (Chong et al, 2001(Chong et al, , 2002Mooney et al, 2002a;Opperman et al, 2002b) (Moursi et al, unpublished data).…”

Section: Discussionmentioning

confidence: 99%

Rescue of coronal suture fusion using transforming growth factor‐beta 3 (Tgf‐β3) in rabbits with delayed‐onset craniosynostosis

et al. 2003

View full text Add to dashboard Cite

Craniosynostosis results in cranial deformities and increased intracranial pressure, which pose extensive and recurrent surgical management problems. Developmental studies in rodents have shown that low levels of transforming growth factor-␤3 (Tgf-␤3) are associated with normal fusion of the interfrontal (IF) suture, and that Tgf-␤3 prevents IF suture fusion in a dose-dependent fashion. The present study was designed to test the hypothesis that Tgf-␤3 can also prevent or "rescue" fusing sutures in a rabbit model with familial craniosynostosis. One hundred coronal sutures from 50 rabbits with delayed-onset, coronal suture synostosis were examined in the present study. The rabbits were divided into five groups of 10 rabbits each: 1) sham controls, 2) bovine serum albumin (BSA, 500 ng) low-dose protein controls, 3) low-dose Tgf-␤3 (500 ng), 4) high-dose BSA (1,000 ng) controls, and 5) high-dose Tgf-␤3 (1,000 ng). At 10 days of age, radiopaque amalgam markers were implanted in all of the rabbits on either side of the coronal suture to monitor sutural growth. At 25 days of age, the BSA or Tgf-␤3 was combined with a slow-absorbing collagen vehicle and injected subperiosteally above the coronal suture. Radiographic results revealed that high-dose Tgf-␤3 rabbits had significantly greater (P Ͻ 0.05) coronal suture marker separation than the other groups. Histomorphometric analysis revealed that high-dose Tgf-␤3 rabbits also had patent coronal sutures and significantly (P Ͻ 0.01) greater sutural widths and areas than the other groups. The results suggest that there is a dose-dependent effect of TGF-␤3 on suture morphology and area in these rabbits, and that the manipulation of such growth factors may have clinical applications in the treatment of craniosynostosis. Anat Rec Part A 274A: 962-971, 2003.

show abstract

Section: Discussionmentioning

confidence: 99%

Rescue of coronal suture fusion using transforming growth factor‐beta 3 (Tgf‐β3) in rabbits with delayed‐onset craniosynostosis

et al. 2003

View full text Add to dashboard Cite

show abstract

“…Growth factor release from such systems was enhanced through cleavage of the heparin bond by heparinases. [64] Numerous groups have used this concept to stabilize and to facilitate delivery of various growth factors including transforming growth factor b2 (TGF-b2), [65] brain and pituitary fibroblast growth factors (FGFs), [66] epidermal growth factor (EGF), [67] and basic fibroblast growth factor (bFGF). [64] Although these systems used heparin to stabilize the growth factor, the specific interaction between heparin and growth factors in these instances was not used to control release.…”

Section: Heparin Binding For Growth Factor Immobilization and Presentmentioning

confidence: 99%

Affinity‐Based Drug Delivery

Wang

Recum

2010

Macromolecular Bioscience

179

146

View full text Add to dashboard Cite

Affinity-based drug delivery systems utilize interactions between the therapeutic drug and the delivery system to manipulate drug loading and to control drug release. In this paper, affinity-based drug delivery system syntheses, types of therapeutic factors delivered, and delivery system loading and release are discussed in detail. The paper is divided into three subsections, based on the type of delivery system: molecular imprinting systems, growth-factor delivery, and cyclodextrin-based delivery. The objective of this paper is to examine the current state of research, highlight the breakthroughs and challenges, point out potential impacts of this relatively new technology, and explore future developmental areas.

show abstract

“…In a mink lung cell bioassay, Tgf-␤2 admixed with gel retained a level of activity similar to that of Tgf-␤2 alone (Bentz et al, 1998;Schroeder-Tefft et al, 1997). In vivo, Tgf-␤2 in collagen gel induced a typical subcutaneous fibroblastic response, indicating that the growth factor retained its biological activity in the gel (Schroeder-Tefft et al, 1997). Although highly purified, this formulation retains the native fibrillar conformation of collagen, as opposed to other commercially available degraded collagen gels.…”

Section: Discussionmentioning

confidence: 86%

“…Various types of collagen biomaterials have been tested as drug delivery vehicles (Friess, 1998), and delivery of growth factors using this particular gel has been evaluated (Schroeder-Tefft et al, 1997;Bentz et al, 1998). In a mink lung cell bioassay, Tgf-␤2 admixed with gel retained a level of activity similar to that of Tgf-␤2 alone (Bentz et al, 1998;Schroeder-Tefft et al, 1997).…”

Section: Discussionmentioning

confidence: 99%

Transforming growth factor‐beta 3(Tgf‐β3) in a collagen gel delays fusion of the rat posterior interfrontal suture in vivo

Opperman¹,

Moursi²,

Sayne³

et al. 2002

Anat. Rec.

View full text Add to dashboard Cite

Postnatal expansion of the intramembranous bones of the craniofacial skeleton occurs as bone growth at sutures. Loss of the bone growth site occurs when the suture fails to form, or when the newly formed sutures become ossified, resulting in premature obliteration. Previous experiments demonstrated that removal of dura mater from fetal rat coronal sutures, or neutralizing transforming growth factor-beta 2 (Tgf-␤2) activity using antibodies resulted in premature obliteration of the suture in vitro. Conversely, addition of Tgf-␤3 to coronal sutures in vitro rescued them from osseous obliteration. To examine whether Tgf-␤3 rescues sutures from obliteration in vivo, a collagen gel was used as a vehicle to deliver Tgf-␤3 to the normally fusing rat posterior interfrontal (IF) suture. Surgery was done on postnatal day 9 (P9) rats, in which collagen gels containing 0, 3, or 30 ng Tgf-␤3 were placed above the IF suture, underneath the periosteum for 2 weeks. By P24, 75-100% of animals in control unoperated, sham-operated, and collagen gel-only groups had fused IF sutures. In contrast, 40% of sutures exposed to 3 ng Tgf-␤3 remained open, while sutures exposed to 30 ng Tgf-␤ were similar to controls. By immunohistochemistry, sutures rescued from obliteration by Tgf-␤3 had the same Tgf-␤ receptor type II (T␤r-II) distribution as controls. However, Tgf-␤3-treated sutures had altered Tgf-␤2 and T␤r-I distribution compared to controls. Anat Rec 267: 120 -130, 2002.

show abstract

Collagen and heparin matrices for growth factor delivery

Cited by 36 publications

References 12 publications

Rescue of coronal suture fusion using transforming growth factor‐beta 3 (Tgf‐β3) in rabbits with delayed‐onset craniosynostosis

Rescue of coronal suture fusion using transforming growth factor‐beta 3 (Tgf‐β3) in rabbits with delayed‐onset craniosynostosis

Affinity‐Based Drug Delivery

Transforming growth factor‐beta 3(Tgf‐β3) in a collagen gel delays fusion of the rat posterior interfrontal suture in vivo

Contact Info

Product

Resources

About